Hims & Hers Health (HIMS) to Release Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is expected to post its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect Hims & Hers Health to post earnings of $0.04 per share and revenue of $619.4790 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 23, 2026 at 5:00 PM ET.

Hims & Hers Health Stock Up 3.2%

HIMS stock opened at $16.31 on Monday. The stock has a 50-day simple moving average of $30.86 and a two-hundred day simple moving average of $41.81. Hims & Hers Health has a twelve month low of $15.63 and a twelve month high of $72.98. The firm has a market capitalization of $3.71 billion, a PE ratio of 30.21, a PEG ratio of 3.04 and a beta of 2.43. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health declared that its board has approved a share repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on HIMS shares. BTIG Research decreased their target price on shares of Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. KeyCorp initiated coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. UBS Group set a $32.00 price objective on Hims & Hers Health in a research note on Tuesday, November 4th. Finally, Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $39.32.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the transaction, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the sale, the insider owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 82,963 shares of company stock worth $2,944,621 in the last quarter. 17.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after purchasing an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health in the first quarter worth about $30,000. EverSource Wealth Advisors LLC lifted its stake in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares during the last quarter. Amundi lifted its stake in shares of Hims & Hers Health by 5.3% in the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock valued at $489,000 after acquiring an additional 522 shares during the last quarter. Finally, California Public Employees Retirement System boosted its holdings in Hims & Hers Health by 9.5% during the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after acquiring an additional 29,471 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.